Clinical applications of positron emission tomography in sarcoma management

Expert Review of Anticancer Therapy

Volumn 11, Issue 2, 2011, Pages 195-204

  Quak, Elske ^a   Van De Luijtgaarden, Addy C M ^a   De Geus Oei, Lioe Fee ^a   Van Der Graaf, Winette T A ^a   Oyen, Wim J G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

FDG PET; GIST; glucose metabolism; grade; prognosis; sarcoma; stage; therapeutic response

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IMATINIB; POLYPHOSPHORIC ACID TC 99M; TRACER;

CANCER GRADING; CANCER STAGING; DRUG HALF LIFE; DRUG UPTAKE; EWING SARCOMA; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMAGING; METASTASIS; OSTEOSARCOMA; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; SARCOMA; TREATMENT RESPONSE; TUMOR BIOPSY;

FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASM STAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SARCOMA;

EID: 79952119236     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.133     Document Type: Review

References (68)

1. Plathow C, Weber WA. Tumor cell metabolism imaging. J. Nucl. Med. 49(Suppl. 2), 43S-63S (2008).
2. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat. Rev. Cancer 2(9), 683-693 (2002).
3. Buerkle A, Weber WA. Imaging of tumor glucose utilization with positron emission tomography. Cancer Metastasis Rev. 27(4), 545-554 (2008).
4. 18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest. Radiol. 22(5), 360-371 (1987).
5. Di Chiro G, Hatazawa J, Katz DA, Rizzoli HV, De Michele DJ. Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study. Radiology 164(2), 521-526 (1987).
6. Vriens D, Visser EP, de Geus-Oei LF, Oyen WJ. Methodological considerationsin quantification of oncological FDG PET studies. Eur. J. Nucl. Med. Mol. Imaging 37(7), 1408-1425 (2009).
7. Kern KA, Brunetti A, Norton JA et al. Metabolic imaging of human extremity musculoskeletal tumors by PET. J. Nucl. Med. 29(2), 181-186 (1988).
8. Schulte M, Brecht-Krauss D, Heymer B et al. Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET. J. Nucl. Med. 41(10), 1695-1701 (2000).
9. Schulte M, Brecht-Krauss D, Heymer B et al. Fluorodeoxyglucose positron emission tomography of soft tissue tumours: is a non-invasive determination of biological activity possible? Eur. J. Nucl. Med. 26(6), 599-605 (1999).
10. Adler LP, Blair HF, Makley JT et al. Noninvasive grading of musculoskeletal tumors using PET. J. Nucl. Med. 32(8), 1508-1512 (1991).
11. Nieweg OE, Pruim J, van Ginkel RJ et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J. Nucl. Med. 37(2), 257-261 (1996).
12. Brenner W, Eary JF, Hwang W, Vernon C, Conrad EU. Risk assessment in liposarcoma patients based on FDG PET imaging. Eur. J. Nucl. Med. Mol. Imaging 33(11), 1290-1295 (2006).
13. 18F] fluorodeoxyglucose positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 33(6), 683-691 (2006).
14. Punt SE, Eary JF, O'Sullivan J, Conrad EU. Fluorodeoxyglucose positron emission tomography in leiomyosarcoma: imaging characteristics. Nucl. Med. Commun. 30(7), 546-549 (2009).
15. Schwarzbach MH, Dimitrakopoulou-Strauss A, Willeke F et al. Clinical value of [18-F] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann. Surg. 231(3), 380-386 (2000).
16. Charest M, Hickeson M, Lisbona R, Novales-Diaz JA, Derbekyan V, Turcotte RE. FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases. Eur. J. Nucl. Med. Mol. Imaging DOI: 10.1007/s00259-009-1203-0 (2009) (Epub ahead of print).
17. Hicks RJ. Functional imaging techniques for evaluation of sarcomas. Cancer Imaging 5(1), 58-65 (2005).
18. Jager PL, Hoekstra HJ, Leeuw J, van der Graaf WT, de Vries EG, Piers D. Routine bone scintigraphy in primary staging of soft tissue sarcoma: is it worthwhile? Cancer 89(8), 1726-1731 (2000).
19. Tateishi U, Hosono A, Makimoto A et al. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma. Ann. Nucl. Med. 23(2), 155-161 (2009).
20. Mody RJ, Bui C, Hutchinson RJ et al. FDG PET imaging of childhood sarcomas. Pediatr. Blood Cancer 54(2), 222-227 (2010).
21. 18F-fluoro-2-deoxy-glucose positron emission tomography (FDG-PET) and conventional imaging modalities improve staging significantly compared with conventional imaging modalities alone, with 91% correct therapy decisions when side-by-side analysis is used.
22. Gerth HU, Juergens KU, Dirksen U, Gerss J, Schober O, Franzius C. Significant benefit of multimodal imaging: PET/CT compared with PET alone in staging and follow-up of patients with Ewing tumors. J. Nucl. Med. 48(12), 1932-1939 (2007).
23. Piperkova E, Mikhaeil M, Mousavi A et al. Impact of PET and CT in PET/CT studies for staging and evaluating treatment response in bone and soft tissue sarcomas. Clin. Nucl. Med. 34(3), 146-150 (2009).
24. Franzius C, Sciuk J, Daldrup-Link HE, Jurgens H, Schober O. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur. J. Nucl. Med. 27(9), 1305-1311 (2000).
25. Franzius C, Daldrup-Link HE, Sciuk J et al. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann. Oncol. 12(4), 479-486 (2001).
26. 18F-FDG PET and PET/CT for detection of pulmonary metastases from musculoskeletal sarcomas. Nucl. Med. Commun. 27(10), 795-802 (2006).
27. Pisters PW, Patel SR, Varma DG et al. Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution. J. Clin. Oncol. 15(12), 3481-3487 (1997).
28. DeLaney TF, Spiro IJ, Suit HD et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int. J. Radiat. Oncol. Biol. Phys. 56(4), 1117-1127 (2003).
29. Kraybill WG, Harris J, Spiro IJ et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. J. Clin. Oncol. 24(4), 619-625 (2006).
30. Benz MR, Czernin J, Allen-Auerbach MS et al. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin. Cancer Res. 15(8), 2856-2863 (2009). Prospective study of 50 patients with soft-tissue sarcomas shows that early-response monitoring to neoadjuvant therapy with FDG-PET is a sensitive predictor of histopathologic response.
31. Weber WA, Figlin R. Monitoring cancer treatment with PET/CT: does it make a difference? J. Nucl. Med. 48(Suppl. 1), 36S-44S (2007).
32. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann. Surg. 231(1), 51-58 (2000).
33. Connolly EM, Gaffney E, Reynolds JV. Gastrointestinal stromal tumours. Br. J. Surg. 90(10), 1178-1186 (2003).
34. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347(7), 472-480 (2002).
35. Choi H. Response evaluation of gastrointestinal stromal tumors. Oncologist 13(Suppl. 2), 4-7 (2008).
36. 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur. J. Cancer 39(14), 2012-2020 (2003). Spectacular results in this early-response monitoring study of gastrointestinal stromal tumors after initiating imatinib mesylate therapy. FDG-PET predicted response as early as 24-48 h after the start of treatment, and preceded the computed tomography response by a median of 7 weeks.
37. Antoch G, Kanja J, Bauer S et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J. Nucl. Med. 45(3), 357-365 (2004).
38. 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J. Nucl. Med. 45(1), 17-21 (2004).
39. Jager PL, Gietema JA, van der Graaf WT. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nucl. Med. Commun. 25(5), 433-438 (2004).
40. Van den Abbeele AD. The lessons of GIST-PET and PET/CT: a new paradigm for imaging. Oncologist 13(Suppl. 2), 8-13 (2008).
41. Holdsworth CH, Badawi RD, Manola JB et al. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. AJR Am. J. Roentgenol. 189(6), W324-W330 (2007).
42. 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J. Clin. Oncol. 27(3), 439-445 (2009).
43. Evilevitch V, Weber WA, Tap WD et al. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin. Cancer Res. 14(3), 715-720 (2008). Prospective study in 42 patients with high-grade STS showing that prediction of histopathologic response to neoadjuvant treatment with FDG-PET is significantly more accurate than size-based criteria (Response Evaluation Criteria In Solid Tumors [RECIST]).
44. Schuetze SM, Rubin BP, Vernon C et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 103(2), 339-348 (2005).
45. 18F-FDG PET and MRI. J. Nucl. Med. 50(9), 1435-1440 (2009).
46. 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. J. Nucl. Med. 50(3), 340-347 (2009). Retrospective study in 31 osteosarcoma patients shows that FDG-PET can predict overall survival, progression-free survival and tumor necrosis.
47. Hamada K, Tomita Y, Inoue A et al. Evaluation of chemotherapy response in osteosarcoma with FDG-PET. Ann. Nucl. Med. 23(1), 89-95 (2009).
48. Hawkins DS, Rajendran JG, Conrad EU 3rd, Bruckner JD, Eary JF. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-d- glucose positron emission tomography. Cancer 94(12), 3277-3284 (2002).
49. 18F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study. J. Nucl. Med. 51(4), 551-558 (2010).
50. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur. J. Cancer 35(13), 1773-1782 (1999).
51. 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J. Nucl. Med. 47(6), 1059-1066 (2006).
52. 18Fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma. Pediatr. Blood Cancer 49(7), 901-905 (2007).
53. Franzius C, Daldrup-Link HE, Wagner-Bohn A et al. FDG-PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging. Ann. Oncol. 13(1), 157-160 (2002).
54. Johnson GR, Zhuang H, Khan J, Chiang SB, Alavi A. Roles of positron emission tomography with fluorine-18-deoxyglucose in the detection of local recurrent and distant metastatic sarcoma. Clin. Nucl. Med. 28(10), 815-820 (2003).
55. 18F]fluorodeoxyglucose. Ann. Surg. Oncol. 4(1), 57-63 (1997).
56. Park JY, Kim EN, Kim DY et al. Role of PET or PET/CT in the post-therapy surveillance of uterine sarcoma. Gynecol. Oncol. 109(2), 255-262 (2008).
57. Kneisl JS, Patt JC, Johnson JC, Zuger JH. Is PET useful in detecting occult nonpulmonary metastases in pediatric bone sarcomas? Clin. Orthop. Relat. Res. 450, 101-104 (2006).
58. Postovsky S, Barzilai M, Meller I, Kollander Y, Futerman B, Ben Arush MW. Does regular follow-up influence the survival of patients with sarcoma after recurrence? The Miri Shitrit pediatric oncology department experience. J. Pediatr. Hematol. Oncol. 30(3), 189-195 (2008).
59. Brenner W, Conrad EU, Eary JF. FDG PET imaging for grading and prediction of outcome in chondrosarcoma patients. Eur. J. Nucl. Med. Mol. Imaging 31(2), 189-195 (2004).
60. Lisle JW, Eary JF, O'Sullivan J, Conrad EU. Risk assessment based on FDG-PET imaging in patients with synovial sarcoma. Clin. Orthop. Relat. Res. 467(6), 1605-1611 (2009).
61. 18F] Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J. Clin. Oncol. 23(34), 8828-8834 (2005).
62. Hawkins DS, Conrad EU 3rd, Butrynski JE, Schuetze SM, Eary JF. [F-18]-fluorodeoxy-d-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults. Cancer 115(15), 3519-3525 (2009).
63. 18F-FDG uptake as a predictor of patient outcome. J. Nucl. Med. 49(12), 1973-1979 (2008).
64. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J. Nucl. Med. 50(Suppl. 1), 122S-150S (2009).
65. Van Glabbeke M, Verweij J, Judson I, Nielsen OS. Progression-free rate as the principal end-point for Phase II trials in soft-tissue sarcomas. Eur. J. Cancer 38(4), 543-549 (2002).
66. 18F]fluorodeoxythymidine. Clin. Cancer Res. 14(10), 2970-2977 (2008).
67. Meyer JS, Nadel HR, Marina N et al. Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee. Pediatr. Blood Cancer 51(2), 163-170 (2008).
68. Fahey FH. Dosimetry of pediatric PET/CT. J. Nucl. Med. 50(9), 1483-1491 (2009). Clear and comprehensive review describing the physical aspects of PET and computed tomography, radiation dosimetry and the potential harm of radiation. Provides advice on reducing the effective dose without compromising image quality is given.